CRISPR Therapeutics
Update in progressCRSP (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
CRISPR Therapeutics AG is a gene-editing company using CRISPR/Cas9 technology to develop medicines for serious diseases. Its lead candidate, CASGEVY, edits patients’ hematopoietic stem cells to raise fetal hemoglobin for transfusion-dependent beta-thalassemia, severe SCD, and related hemoglobinopathies. It also advances CAR T therapies (CTX112, CTX131), in vivo editing (CTX310, CTX320), and allogeneic hypoimmune stem cell programs (CTX211), with Vertex as a partner. Founded in 2013 and based in Zug, Switzerland.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- -0.23
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.10
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!